P060 Measurement of the plasma concentration of elexacaftor/tezacaftor/ivacaftor (ETI) by LC/MS-MS in a patient with cystic fibrosis during pregnancy

Abstract

Background: Cystic Fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene that make the CFTR protein dysfunctional, making secretions sticky. CF people can have a variety of symptoms, including infertility. In 2020, a triple combination therapy of elexacaftor/tezacaftor plus ivacaftor (ETI) was approved by EMA, capable of correcting the malfunction of the CFTR protein. The improvement in clinical conditions and life expectancy leads to an increase in the number of pregnancies. The effects of this drug on the mother and newborn are not yet fully known.